PTX Stock Overview
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Prescient Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.058 |
| 52 Week High | AU$0.10 |
| 52 Week Low | AU$0.044 |
| Beta | 1.1 |
| 1 Month Change | 20.83% |
| 3 Month Change | 1.75% |
| 1 Year Change | -36.96% |
| 3 Year Change | -39.58% |
| 5 Year Change | 31.82% |
| Change since IPO | -99.92% |
Recent News & Updates
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12
We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Recent updates
We Think Prescient Therapeutics (ASX:PTX) Can Afford To Drive Business Growth
Mar 12We're Not Very Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Rate
Nov 14Companies Like Prescient Therapeutics (ASX:PTX) Are In A Position To Invest In Growth
Aug 01Shareholders Would Not Be Objecting To Prescient Therapeutics Limited's (ASX:PTX) CEO Compensation And Here's Why
Nov 22Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation
Oct 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Jun 19Prescient Therapeutics (ASX:PTX) Is In A Strong Position To Grow Its Business
Feb 27We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Prescient Therapeutics Limited's (ASX:PTX) CEO For Now
Nov 05We Think Prescient Therapeutics (ASX:PTX) Can Easily Afford To Drive Business Growth
Aug 26Prescient Therapeutics (ASX:PTX) Is In A Good Position To Deliver On Growth Plans
May 08Does Prescient Therapeutics' (ASX:PTX) CEO Salary Compare Well With The Performance Of The Company?
Jan 11
Shareholder Returns
| PTX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -1.7% | 1.9% | 0.9% |
| 1Y | -37.0% | -7.7% | 5.6% |
Return vs Industry: PTX underperformed the Australian Biotechs industry which returned -7.7% over the past year.
Return vs Market: PTX underperformed the Australian Market which returned 5.6% over the past year.
Price Volatility
| PTX volatility | |
|---|---|
| PTX Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: PTX has not had significant price volatility in the past 3 months.
Volatility Over Time: PTX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Steven Yatomi-Clarke | ptxtherapeutics.com |
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR.
Prescient Therapeutics Limited Fundamentals Summary
| PTX fundamental statistics | |
|---|---|
| Market cap | AU$46.71m |
| Earnings (TTM) | -AU$7.74m |
| Revenue (TTM) | AU$3.11m |
15.0x
P/S Ratio-6.0x
P/E RatioIs PTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTX income statement (TTM) | |
|---|---|
| Revenue | AU$3.11m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$3.11m |
| Other Expenses | AU$10.86m |
| Earnings | -AU$7.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0096 |
| Gross Margin | 100.00% |
| Net Profit Margin | -248.74% |
| Debt/Equity Ratio | 0% |
How did PTX perform over the long term?
See historical performance and comparison